Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

35
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
35
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Does HDL-C matter when predicting risk of cardiovascular disease in older people with type 2 diabetes?

European journal of preventive cardiology·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.

European journal of clinical investigation·2026
Same author

Thyroid dysfunction and cardiovascular disease.

European heart journal·2026
Same author

[How will artificial intelligence improve cardiovascular prevention?]

Revue medicale suisse·2026

Related Experiment Video

Updated: Apr 15, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK9 inhibitors.

Baris Gencer1, Gilles Lambert2, François Mach1

  • 1Cardiology Division, Geneva University Hospitals, Switzerland.

Swiss Medical Weekly
|April 10, 2015
PubMed
Summary
This summary is machine-generated.

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibition effectively lowers LDL cholesterol. Clinical trials show PCSK9 antibodies significantly reduce LDL-C, offering a promising new therapy for cardiovascular disease risk management.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.4K

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Pharmacology

Background:

  • Proprotein convertase subtilisin kexin 9 (PCSK9) regulates low-density lipoprotein cholesterol (LDL-C) receptor levels.
  • PCSK9 inhibition is a novel therapeutic strategy for managing hypercholesterolemia.
  • Gain-of-function mutations in PCSK9 are linked to familial hypercholesterolemia and increased cardiovascular disease (CVD) risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of PCSK9 inhibition in lowering LDL-C levels.
  • To assess the potential of PCSK9 antibodies as a therapeutic option for patients with hypercholesterolemia.
  • To investigate the impact of PCSK9 inhibition on cardiovascular events in high-risk patients.

Main Methods:

  • Clinical development of human monoclonal antibodies targeting PCSK9.
  • Phase I, II, and III clinical trials in patients with familial hypercholesterolemia, statin intolerance, and acute coronary syndrome.
  • Regular subcutaneous injections of PCSK9 inhibitors were administered.

Main Results:

  • Phase II studies demonstrated a 60%-70% reduction in LDL-C levels with PCSK9 antibody treatment.
  • PCSK9 inhibition showed a favorable safety profile, with injection site reactions as the primary side effect.
  • Large-scale Phase III trials are ongoing to confirm the effect on CVD events in acute coronary syndrome patients.

Conclusions:

  • PCSK9 inhibition represents a significant advancement in lipid management, offering substantial LDL-C reduction.
  • Anti-PCSK9 monoclonal antibodies are a safe and effective therapeutic option for managing hypercholesterolemia and reducing cardiovascular risk.
  • Ongoing research will further elucidate the role of PCSK9 inhibition in preventing major adverse cardiovascular events.